Leslie Trigg, CEO of Outset Medical (OM), has been selling small lots of stock consistently throughout 2026 — while the company is in the middle of a margin-rebuild turnaround story.
Small, frequent sales from a CEO of a company pitching a recovery narrative. Is that a contradiction? Not necessarily.
The pattern
- Who: Leslie Trigg, CEO of Outset Medical
- What: Multiple small-lot sales over consecutive periods
- Pattern: Drip selling — regular, small amounts rather than large blocks
- Context: Outset Medical is a medtech company rebuilding margins after a challenging period
What drip selling looks like
Unlike large block sales ($10M+ in one transaction), drip selling involves:
- Selling 1,000-5,000 shares at a time
- Multiple transactions per month or quarter
- Dollar amounts in the tens of thousands to low hundreds of thousands per transaction
- Consistent cadence (e.g., every 2 weeks)
This is the fingerprint of a 10b5-1 plan with frequent small execution intervals.
Why drip selling during a turnaround is nuanced
The concern
If the CEO truly believes in the margin-rebuild story, why sell at all? Shouldn't they be holding (or buying) into the recovery?
The reality for small-cap CEOs
Outset Medical is a small-cap medtech company. CEO compensation at this scale has specific dynamics:
- Salary is modest relative to large-cap: Small-cap CEOs often earn $500K-$1M in base salary
- Equity is the majority of compensation: Stock grants make up 60-80% of total comp
- Liquidity needs are real: The CEO needs cash for living expenses, taxes, and diversification
- The stock may be illiquid: Small-cap stocks have wider spreads and lower volume — selling in small lots minimizes market impact
Drip selling ≠ dumping
A CEO drip-selling $50K every two weeks is managing liquidity. A CEO dumping $5M in one day is making a statement. The frequency and size of Trigg's sales suggest the former.
The turnaround context
Outset Medical's situation:
- Product: Tablo hemodialysis system (designed to simplify dialysis)
- Challenge: Margin pressure from manufacturing costs and slower-than-expected adoption
- Story: Management pitching a path to margin expansion through scale and cost reduction
- Stock: Trading well below IPO levels
Why the turnaround story matters for insider analysis
In turnaround situations, insider activity carries more weight than in stable companies:
| Insider action | In a stable company | In a turnaround |
|---|---|---|
| Small regular selling | Noise | Slightly concerning — CEO should be maximally aligned |
| Large selling | Diversification | More concerning — selling into uncertainty |
| Buying | Bullish | Very bullish — conviction in the recovery |
| No activity | Neutral | Mildly negative — not adding during dip |
Trigg's drip selling falls in the "slightly concerning" category — not because the amounts are meaningful, but because the turnaround narrative would be more convincing with insider buying.
The small-cap insider data challenge
Small-cap insider data is inherently noisier than large-cap:
- Fewer insiders: A company with 3-4 reporting insiders has a tiny sample size
- Compensation-driven: A larger percentage of sales are compensation-related
- Liquidity constraints: Insiders can't easily sell large amounts without moving the stock
- Less analyst coverage: Fewer external checks on the company's narrative
- Higher impact: Each insider transaction represents a larger percentage of typical daily volume
What would strengthen the turnaround thesis
From insider data
- Trigg stopping her selling plan: Choosing to retain more = increased conviction
- Any open-market purchase from any insider: Would be a powerful signal given the depressed stock price
- Board members buying: Directors adding shares at current prices = governance-level conviction
From 13F data
- Healthcare-focused hedge fund initiating a position: Smart money seeing value
- Existing institutional holders increasing shares: Adding into weakness = conviction
- Institutional holder count growing: Broadening interest despite the stock's challenges
From fundamentals
- Tablo placement growth rate
- Gross margin trajectory (the key metric for the turnaround thesis)
- Cash burn rate and runway
- New contract announcements (health systems, VA hospitals)
The bottom line
CEO drip-selling during a turnaround isn't ideal optics, but it's not necessarily bearish. The amounts are small, the pattern is consistent with a 10b5-1 plan, and small-cap CEO liquidity needs are real.
The stronger signal would be what ISN'T happening: no insider buying during a period when the stock is depressed and management is pitching recovery. The absence of buying is more informative than the presence of small selling.
Originally published at 13F Insight
Top comments (0)